Hi all
The report states that finished spodumene concentrate stock was written down to a net realisable value of $6,933,000. According to the quarterly activities report, spodumene concentrate stock on hand at 30 June 2020 was 17,978 dmt. That puts it at $385 per dmt. Is this stock lower spec product or does it reflect management's expectation of realised prices for the year ahead?
With prices as low as they are, PLS needs to get as far up that cost curve as possible this year. There are murmurs that Chinese stockpiles are starting to slowly run down. Could this mean that PLS's offtake partners are in a position to start receiving increased product quantities this year? If not, we must be getting fairly close to C&M?
Cheers.
Ann: 2020 Annual Financial Report Announcement, page-85
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.16 |
Change
0.170(5.69%) |
Mkt cap ! $9.515B | |||
| Open | High | Low | Value | Volume |
| $3.10 | $3.20 | $3.05 | $117.6M | 37.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 72180 | $3.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.17 | 222212 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PLS (ASX) Chart |